1
|
Anderson BD, Sepulveda DE, Nachnani R, Cortez-Resendiz A, Coates MD, Beckett A, Bisanz JE, Kellogg JJ, Raup-Konsavage WM. High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model. J Pharmacol Exp Ther 2024; 390:331-341. [PMID: 39009468 PMCID: PMC11338277 DOI: 10.1124/jpet.124.002204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2024] [Revised: 05/21/2024] [Accepted: 06/21/2024] [Indexed: 07/17/2024] Open
Abstract
Cannabis sativa L. has a long history of medicinal use, particularly for gastrointestinal diseases. Patients with inflammatory bowel disease (IBD) report using cannabis to manage their symptoms, despite little data to support the use of cannabis or cannabis products to treat the disease. In this study, we use the well-described dextran sodium sulfate (DSS) model of colitis in mice to assess the impact of commercially available, noneuphorigenic, high cannabigerol (CBG) hemp extract (20 mg/mL cannabigerol, 20.7 mg/mL cannabidiol, 1 mg/mL cannabichromene) on IBD activity and the colonic microbiome. Mice were given 2% DSS in drinking water for 5 days, followed by 2 days of regular drinking water. Over the 7 days, mice were dosed daily with either high CBG hemp extract or matched vehicle control. Daily treatment with high CBG hemp extract dramatically reduces the severity of disease at the histological and organismal levels as measured by decreased disease activity index, increased colon length, and decreases in percent colon tissue damage. 16S rRNA gene sequencing of the fecal microbiota reveals high CBG hemp extract treatment results in alterations in the microbiota that may be beneficial for colitis. Finally, using metabolomic analysis of fecal pellets, we find that mice treated with high CBG hemp extract have a normalization of several metabolic pathways, including those involved in inflammation. Taken together, these data suggest that high CBG hemp extracts may offer a novel treatment option for patients. SIGNIFICANCE STATEMENT: Using the dextran sodium sulfate model of colitis, the authors show that treatment with high cannabigerol hemp extract reduces the severity of symptoms associated with colitis. Additionally, they show that treatment modulates both the fecal microbiota and metabolome with potential functional significance.
Collapse
Affiliation(s)
- Benjamin D Anderson
- Departments of Biochemistry and Molecular Biology (B.D.A., A.B.) and Veterinary and Biomedical Sciences (J.J.K.), and One Health Microbiome Center, Huck Life Sciences Institute (J.E.B.), Pennsylvania State University, University Park, Pennsylvania; and Departments of Pharmacology (D.E.S., R.N., A.C.-R., M.D.C., W.M.R.-K.) and Anesthesiology & Perioperative Medicine (D.E.S.), Center for Cannabis & Natural Product Pharmaceutics (D.E.S., R.N., A.C.-R., M.D.C., J.E.B., J.J.K., W.M.R.-K.), and Divison of Gastroenterology & Hepatology, Department of Medicine (M.D.C., J.J.K.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Diana E Sepulveda
- Departments of Biochemistry and Molecular Biology (B.D.A., A.B.) and Veterinary and Biomedical Sciences (J.J.K.), and One Health Microbiome Center, Huck Life Sciences Institute (J.E.B.), Pennsylvania State University, University Park, Pennsylvania; and Departments of Pharmacology (D.E.S., R.N., A.C.-R., M.D.C., W.M.R.-K.) and Anesthesiology & Perioperative Medicine (D.E.S.), Center for Cannabis & Natural Product Pharmaceutics (D.E.S., R.N., A.C.-R., M.D.C., J.E.B., J.J.K., W.M.R.-K.), and Divison of Gastroenterology & Hepatology, Department of Medicine (M.D.C., J.J.K.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Rahul Nachnani
- Departments of Biochemistry and Molecular Biology (B.D.A., A.B.) and Veterinary and Biomedical Sciences (J.J.K.), and One Health Microbiome Center, Huck Life Sciences Institute (J.E.B.), Pennsylvania State University, University Park, Pennsylvania; and Departments of Pharmacology (D.E.S., R.N., A.C.-R., M.D.C., W.M.R.-K.) and Anesthesiology & Perioperative Medicine (D.E.S.), Center for Cannabis & Natural Product Pharmaceutics (D.E.S., R.N., A.C.-R., M.D.C., J.E.B., J.J.K., W.M.R.-K.), and Divison of Gastroenterology & Hepatology, Department of Medicine (M.D.C., J.J.K.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Alonso Cortez-Resendiz
- Departments of Biochemistry and Molecular Biology (B.D.A., A.B.) and Veterinary and Biomedical Sciences (J.J.K.), and One Health Microbiome Center, Huck Life Sciences Institute (J.E.B.), Pennsylvania State University, University Park, Pennsylvania; and Departments of Pharmacology (D.E.S., R.N., A.C.-R., M.D.C., W.M.R.-K.) and Anesthesiology & Perioperative Medicine (D.E.S.), Center for Cannabis & Natural Product Pharmaceutics (D.E.S., R.N., A.C.-R., M.D.C., J.E.B., J.J.K., W.M.R.-K.), and Divison of Gastroenterology & Hepatology, Department of Medicine (M.D.C., J.J.K.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Matthew D Coates
- Departments of Biochemistry and Molecular Biology (B.D.A., A.B.) and Veterinary and Biomedical Sciences (J.J.K.), and One Health Microbiome Center, Huck Life Sciences Institute (J.E.B.), Pennsylvania State University, University Park, Pennsylvania; and Departments of Pharmacology (D.E.S., R.N., A.C.-R., M.D.C., W.M.R.-K.) and Anesthesiology & Perioperative Medicine (D.E.S.), Center for Cannabis & Natural Product Pharmaceutics (D.E.S., R.N., A.C.-R., M.D.C., J.E.B., J.J.K., W.M.R.-K.), and Divison of Gastroenterology & Hepatology, Department of Medicine (M.D.C., J.J.K.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Aviauna Beckett
- Departments of Biochemistry and Molecular Biology (B.D.A., A.B.) and Veterinary and Biomedical Sciences (J.J.K.), and One Health Microbiome Center, Huck Life Sciences Institute (J.E.B.), Pennsylvania State University, University Park, Pennsylvania; and Departments of Pharmacology (D.E.S., R.N., A.C.-R., M.D.C., W.M.R.-K.) and Anesthesiology & Perioperative Medicine (D.E.S.), Center for Cannabis & Natural Product Pharmaceutics (D.E.S., R.N., A.C.-R., M.D.C., J.E.B., J.J.K., W.M.R.-K.), and Divison of Gastroenterology & Hepatology, Department of Medicine (M.D.C., J.J.K.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Jordan E Bisanz
- Departments of Biochemistry and Molecular Biology (B.D.A., A.B.) and Veterinary and Biomedical Sciences (J.J.K.), and One Health Microbiome Center, Huck Life Sciences Institute (J.E.B.), Pennsylvania State University, University Park, Pennsylvania; and Departments of Pharmacology (D.E.S., R.N., A.C.-R., M.D.C., W.M.R.-K.) and Anesthesiology & Perioperative Medicine (D.E.S.), Center for Cannabis & Natural Product Pharmaceutics (D.E.S., R.N., A.C.-R., M.D.C., J.E.B., J.J.K., W.M.R.-K.), and Divison of Gastroenterology & Hepatology, Department of Medicine (M.D.C., J.J.K.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Joshua J Kellogg
- Departments of Biochemistry and Molecular Biology (B.D.A., A.B.) and Veterinary and Biomedical Sciences (J.J.K.), and One Health Microbiome Center, Huck Life Sciences Institute (J.E.B.), Pennsylvania State University, University Park, Pennsylvania; and Departments of Pharmacology (D.E.S., R.N., A.C.-R., M.D.C., W.M.R.-K.) and Anesthesiology & Perioperative Medicine (D.E.S.), Center for Cannabis & Natural Product Pharmaceutics (D.E.S., R.N., A.C.-R., M.D.C., J.E.B., J.J.K., W.M.R.-K.), and Divison of Gastroenterology & Hepatology, Department of Medicine (M.D.C., J.J.K.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Wesley M Raup-Konsavage
- Departments of Biochemistry and Molecular Biology (B.D.A., A.B.) and Veterinary and Biomedical Sciences (J.J.K.), and One Health Microbiome Center, Huck Life Sciences Institute (J.E.B.), Pennsylvania State University, University Park, Pennsylvania; and Departments of Pharmacology (D.E.S., R.N., A.C.-R., M.D.C., W.M.R.-K.) and Anesthesiology & Perioperative Medicine (D.E.S.), Center for Cannabis & Natural Product Pharmaceutics (D.E.S., R.N., A.C.-R., M.D.C., J.E.B., J.J.K., W.M.R.-K.), and Divison of Gastroenterology & Hepatology, Department of Medicine (M.D.C., J.J.K.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| |
Collapse
|
2
|
Chang JY, Park SJ, Park JJ, Kim TI, Cheon JH, Park J. Impact of age at diagnosis on long-term prognosis in patients with intestinal Behçet's disease. J Gastroenterol Hepatol 2024; 39:519-526. [PMID: 38149352 DOI: 10.1111/jgh.16449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Revised: 11/22/2023] [Accepted: 12/03/2023] [Indexed: 12/28/2023]
Abstract
BACKGROUND AND AIM Although age at disease onset is considered to be a significant factor in the prognosis of Crohn's disease, little is known about its influence on the long-term prognosis of those with intestinal Behçet's disease (BD). This study aimed to evaluate the long-term clinical outcomes of patients with intestinal BD according to age of disease onset. METHODS Patients diagnosed with intestinal BD at < 18, 18-60, and > 60 years of age were classified into early-onset, adult-onset, and late-onset groups, respectively. The influence of disease onset time on clinical prognosis, including specific medical requirements, BD-related intestinal surgery, hospitalization, and emergency room visits, was compared using the log-rank test in a large cohort of patients with intestinal BD. RESULTS Among 780 patients, 21 (2.7%), 672 (86.2%), and 87 (11.1%) comprised the early-onset, adult-onset, and late-onset groups, respectively. Patients in the early-onset group were more likely to require immunosuppressants than those in the adult-onset group (P = 0.048). Nine (42.9%), 158 (23.5%), and 18 (20.7%) patients in the early-onset, adult-onset, and late-onset groups, respectively, underwent intestinal resection. The early-onset group exhibited a higher risk for intestinal resection than the late-onset (P = 0.043) and adult-onset (P = 0.030) groups. The late-onset group exhibited a higher risk for BD-related hospitalization than the adult-onset group (P = 0.023). CONCLUSIONS Age at diagnosis affected the clinical course of intestinal BD, including intestinal surgery, hospitalization, and specific medical requirements. Different treatment strategies should be established according to age at diagnosis.
Collapse
Affiliation(s)
- Ji Young Chang
- Department of Health Promotion Medicine, Ewha Womans University Seoul Hospital, Seoul, South Korea
| | - Soo Jung Park
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
- Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
- Inflammatory Bowel Disease Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - Jae Jun Park
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
- Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
- Inflammatory Bowel Disease Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - Tae Il Kim
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
- Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
- Inflammatory Bowel Disease Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - Jae Hee Cheon
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
- Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
- Inflammatory Bowel Disease Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea
| | - Jihye Park
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
- Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
- Inflammatory Bowel Disease Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
| |
Collapse
|
4
|
Xiang J, Li J, Liu C, Tian S, Dong W. Clinical Features of Crohn's Disease Stratified by Age at Diagnosis According to Montreal Classification. J Inflamm Res 2023; 16:737-746. [PMID: 36852301 PMCID: PMC9960709 DOI: 10.2147/jir.s397483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Accepted: 02/11/2023] [Indexed: 02/22/2023] Open
Abstract
Aim The differences of clinical characteristics stratified by age at diagnosis especially according to Montreal classification were rarely studied in China. This study aimed to evaluate and compare the clinical features in various groups of CD patients stratified by age at diagnosis. Methods A cross-sectional study of CD patients was conducted through a stratified sampling according to Montreal classification. Patients were divided into three groups by age at diagnosis: group A1 (<17 years old), group A2 (17 to 40 years old), and group A3 (>40 years old). The clinical characteristics, laboratory tests, radiographic, and endoscopic features were analyzed by statistics. Results We enrolled 259 CD patients for the study. There was male predominance under 40 years old. Compared to group A1, more female patients were presented in group A3. There were more patients had perianal fistulas in group A1 compared to group A2 and group A3. Compared with group A1, patients in group A2 were associated with lower total protein (TP) levels. The mean TP and platelet count (PC) levels in group A3 were lower than group A1. Patients in group A1 had a lower rate of stricturing (B2) disease behavior than group A2 and group A3, and patients in group A3 who had a B2 disease behavior were higher than group A2. Those differences could guide early treatment or inventions for CD patients who might progress to a more complex disease behavior. Conclusion CD patients stratified by age at diagnosis according to Montreal classification had different clinical symptoms, laboratory test results as well as disease locations and behaviors.
Collapse
Affiliation(s)
- Jiankang Xiang
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China
| | - Jiao Li
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China
| | - Chuan Liu
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China
| | - Shan Tian
- Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China
| | - Weiguo Dong
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China,Correspondence: Weiguo Dong, Email
| |
Collapse
|
5
|
Lin J, Zhang M, Zhi M. Clinical characteristics of elderly-onset inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2023; 31:98-104. [DOI: 10.11569/wcjd.v31.i3.98] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Inflammatory bowel disease (IBD) is a group of chronic non-specific intestinal inflammatory diseases whose etiology has not been elucidated. The prevalence of elderly-onset IBD is increasing; however, its disease phenotype, pathophysiology, and clinical characteristics are different from those of adult-onset IBD. In order to better manage elderly IBD patients, it is becoming increasingly important to accurately describe the unique characteristics of elderly-onset IBD. Therefore, this article, based on the domestic and foreign literature reports from 2017 to now, describes the characteristics of elderly-onset IBD with regard to pathogenesis, epidemiological characteristics, clinical features, and treatment.
Collapse
Affiliation(s)
- Jue Lin
- Department of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, Guangdong Province, China
| | - Min Zhang
- Department of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, Guangdong Province, China
| | - Min Zhi
- Department of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, Guangdong Province, China
| |
Collapse
|